Cantor Fitzgerald Suspends Neutral Rating on AtaiBeckley Inc
Cantor Fitzgerald suspends Neutral rating on AtaiBeckley Inc (NASDAQ:ATAI).
Stocks · News reference
President Trump Say In A Social Media Post That The University Of Miami Shared Its 1994 Ibogaine Investigational New Drug Application With The Government, Which Will Help Accelerate Development As A Medical Treatment In The U.S.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — AtaiBeckley Inc. (ATAI)
Filed: 2026-09-11 AccNo: 0001140361-26-036283 Size: 316 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Jim Cramer Isn't Sure If There’s Upside In This Health Care Stock
Cramer favors Howmet, remains cautious on AeroVironment, Rocket, AtaiBeckley and MP Materials, citing competition and limited upside.
AtaiBeckley Says Hart-Scott-Rodino Waiting Period For Merger With Eli Lilly Expired On Aug 28, 2026; UK Competition Authority Has No Further Questions On Merger As Of August 21, 2026
As previously disclosed, AtaiBeckley Inc. (the "Company") entered into an Agreement and Plan of Merger, dated as of July 15, 2026 (the "Merger Agreement"), with Eli Lilly and Company, an Indiana
Psyence Biomedical Completes Investment in PsyLabs Following Milestone Achievement
Psyence Biomedical Ltd. has finalized a $2,599,896 investment in Psyence Labs Ltd. after achieving key regulatory and manufacturing milestones for its ibogaine program.
Psyence Biomedical Completes Its Additional Investment In PsyLabs Of $2,599,896
Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today announced that both milestones attached to its backstop subscription commitment in Psyence Labs Ltd. ("PsyLabs")